Details for New Drug Application (NDA): 020711
✉ Email this page to a colleague
The generic ingredient in ZYBAN is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
Summary for 020711
| Tradename: | ZYBAN |
| Applicant: | Glaxosmithkline |
| Ingredient: | bupropion hydrochloride |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 100MG | ||||
| Approval Date: | May 14, 1997 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | May 14, 1997 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 020711
Complete Access Available with Subscription
